Valeant Pharma to market Mysimba/Contrave (naltrexone HCl / bupropion HCl prolonged release) to treat obesity in Eastern Europe- Orexigen Therapeutics

Orexigen Therapeutics announced that Valeant Pharmaceuticals will commercialise Mysimba (naltrexone HCl / bupropion HCl prolonged release) in Central and Eastern Europe. The distribution agreement between includes 12 countries where Mysimba has been approved for marketing in the European Union (EU): Greece, Slovenia, Slovakia, Czech Republic, Hungary, Croatia, Lithuania, Estonia, Poland, Latvia, Bulgaria and Romania. The agreement also extends to several non-EU countries where Valeant will apply for marketing authorization: Serbia, Bosnia and Herzegovina, Albania, Macedonia, Montenegro, Kosovo and Turkey. Orexigen expects Valeant to launch in the 12 EU countries in the second half of this year.

Under the terms of the agreement, Valeant will be responsible for commercialisation activities in all 19 countries and for obtaining regulatory approvals in the non-EU countries. Orexigen will retain regulatory affairs responsibilities in EU countries. Orexigen will supply Mysimba tablets to Valeant at an agreed transfer price.